12.64
-0.4(-3.07%)
Currency In USD
| Previous Close | 13.04 |
| Open | 12.79 |
| Day High | 12.96 |
| Day Low | 12.52 |
| 52-Week High | 28.25 |
| 52-Week Low | 5.9 |
| Volume | 2.5M |
| Average Volume | 4.84M |
| Market Cap | 1.46B |
| PE | -2.97 |
| EPS | -4.25 |
| Moving Average 50 Days | 11.07 |
| Moving Average 200 Days | 11.99 |
| Change | -0.4 |
If you invested $1000 in Intellia Therapeutics, Inc. (NTLA) since IPO date, it would be worth $571.95 as of February 21, 2026 at a share price of $12.64. Whereas If you bought $1000 worth of Intellia Therapeutics, Inc. (NTLA) shares 5 years ago, it would be worth $191.05 as of February 21, 2026 at a share price of $12.64.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
GlobeNewswire Inc.
Feb 19, 2026 12:30 PM GMT
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will hos
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
GlobeNewswire Inc.
Jan 27, 2026 1:00 PM GMT
Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 12:30 PM GMT
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will pres